Abstract:ObjectiveTo observe the 24-week survival status of patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) treated with plasma exchange (PE) and double plasma molecular adsorption system (DPMAS) alone or in combination, and to establish a predictive model for 24-week prognosis. MethodsRelated clinical data were collected from 133 patients with HBV-ACLF who received PE and DPMAS alone or in combination in The Affiliated Provincial Hospital of Anhui Medical University from January 2015 to December 2019, and according to the survival status at the 24-week follow-up after treatment, they were divided into survival group with 71 patients and death group with 62 patients. A total of 55 patients with HBV-ACLF who received PE and DPMAS alone or in combination in The Second Affiliated Hospital of Anhui Medical University from January 2018 to January 2020 were enrolled as validation group to validate the performance of the model. Related clinical data included mode of artificial liver support therapy, age, sex, total bilirubin (TBil), international normalized ratio (INR), creatinine (Cr), serum sodium, platelet count (PLT), albumin (Alb), and presence or absence of ascites, hepatorenal syndrome, hepatic encephalopathy, and gastrointestinal bleeding. The t-test was used for comparison of normally distributed continuous data between two groups, and the Wilcoxon rank-sum test was used for comparison of continuous data with skewed distribution between two groups; the chi-square test and the Fisher’s exact test were used for comparison of categorical data between groups. The Cox regression model was used to analyze the influencing factors for the prognosis of HBV-ACLF patients after PE and DPMAS alone or in combination and establish a predictive model; the receiver operator characteristic (ROC) curve was plotted and the DeLong method was used to compare the area under the ROC curve (AUC) between the new predictive model and Model for End-Stage Liver Disease (MELD)/MELD combined with serum sodium concentration (MELD-Na) scores. ResultsAt 24 weeks after treatment, 71 patients survived and 62 patients died in the modeling group. The Cox regression analysis showed age (hazard ratio ［HR］=1030, P=0013), TBil (HR=1.018, P＜0.001), INR (HR=1.517, P＜0.001), and PLT (HR=0.993, P=0.04) were independent influencing factors for 24-week survival. According to the results of the Cox regression analysis, a prognostic model for HBV-ACLF patients treated with PE and DPMAS alone or in combination was established as ATIP=0.029×age (years)+0.018×TBil (mg/dL)+0417×INR-0.007×PLT (109/L). Both the modeling group and the validation group showed that the ATIP model had a better predictive performance than MELD and MELD-NA scores(all P＜0.05). ConclusionAge, TBil, INR, and PLT are independent influencing factors for the 24-week survival of HBV-ACLF patients treated with PE and DPMAS alone or in combination, and the ATIP model has a good performance in predicting the 24-week prognosis of HBV-ACLF patients treated with PE and DPMAS alone or in combination.

Mathematics models for plasma exchange

A Plasma Exchange Model and Variation of Bilirubin Concentration

Prediction Value of Model for End-Stage Liver Disease Scoring System on Prognosis in the Acute on Chronic Liver Failure Patients with Plasma Exchange Treatment.

Plasma Exchange Model and Its Application

Models for plasma kinetics during simultaneous therapeutic plasma exchange and extracorporeal membrane oxygenation

Analytical System of Clinical Dosage of Plasma for Artificial Liver

A Prognostic Model for Hepatitis B Acute-on-chronic Liver Failure Patients Treated Using a Plasma Exchange-Centered Liver Support System.

[Economic evaluation of plasma exchange combined with dual plasma adsorption therapy for early, mid and late stage liver failure]

Comparison of Plasma Exchange with Different Membrane Pore Sizes in the Treatment of Severe Viral Hepatitis

Establishment of a Predictive Model for the Prognosis of Patients with Hepatitis B Virus-Related Acute-on-chronic Liver Failure Treated with Plasma Exchange and Double Plasma Molecular Adsorption System Alone or in Combination

Employing New Mathematical Models and Equations to Evaluate Risk-Benefit Criteria of Clinical Therapeutics

Plasma exchange treatment using MELD scoring system improve the prognosis of fulminant Hepatitis in Chinese patients

A Mathematical Model to Predict the Release of Water-Soluble Drugs from Hpmc Matrices

Establishing a Metabolomic Model for the Prognosis of Hepatitis B Virus-Induced Acute-on-chronic Liver Failure Treated with Different Liver Support Systems

Plasma Exchange-Centered Artificial Liver Support System in Hepatitis B Virus-Related Acute-on-chronic Liver Failure: a Nationwide Prospective Multicenter Study in China.

Predicting the Impact of Dialyzer Choice and Binder Dialysate Flow Rate on Bilirubin Removal

Comparitive study of middle and mixed artificial livers in treatment of hepatic failure

Prognostic Models for Acute Liver Failure.

Evaluation of the End-Stage Liver Disease Model in Patients Treated with Plasma Exchange

Analysis of Related Factors on Therapeutic Efficacy of Plasma Exchange for the Treatment of Hyperbilirubinemia

Mathematical modelling of bicarbonate supplementation and acid-base chemistry in kidney failure patients on hemodialysis